Possible new drug for myeloma patients refractory to standard therapy and transplant

Pomalidomide in combination with low-dose dexamethasone has shown a 30% overall response rate in patients with multiple myeloma refractory to Revlimid (lenalidomide), Velcade (bortezomib), or both, including those with prior bone marrow transplant. We look forward to hearing about FDA approval in February 2013.